The anti‐tumoral effect of pyridostatin against the BRCA2‐deficient tumours was similar to talazoparib, and neither drug impaired the growth of BRCA2‐proficient tumours (Fig 1A; Appendix Table S1). This evidence concerns the gene BRCA2 and neoplasm.